Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Oliver Law Group P.C. is Investigating Cases of Melanoma In Men Who Took Sildenafil (Viagra) After Study Finds Potential Link
  • USA - English


News provided by

The Oliver Law Group

Sep 11, 2014, 11:55 ET

Share this article

Share toX

Share this article

Share toX

Viagra Melanoma Lawsuit News: Study Links Viagra Use To Melanoma Skin Cancer
Viagra Melanoma Lawsuit News: Study Links Viagra Use To Melanoma Skin Cancer

Contact the Oliver Law Group P.C. for your free Viagra melanoma skin cancer lawsuit case review by calling 1-800-939-7878 today or visit www.legalactionnow.com

Post this

New York NY (PRWEB) September 11, 2014 -- The Oliver Law Group P.C. reports that a recently published study has found that the use of Sildenafil citrate, sold as Viagra and Revatio increases the risk for developing melanoma skin cancer. Research published in the June 2014 issue of JAMA Internal Medicine showed men who said they used sildenafil, the generic name for Viagra, had an 84 percent risk for having invasive melanoma compared to men who did not use Viagra and other sildenafil drugs. According to researchers, the study’s objective was to evaluate the link between sildenafil use and the melanoma risk among men in the United States. Researchers reviewed data from the Health Professional’s Follow-up Study in which 25,848 men were questioned in 2000 about whether they use sildenafil for erectile dysfunction. The average age of the participants were about 65 years old. Researchers said they identified 142 melanoma cases, 580 squamous cell carcinoma cases and 3,030 cases of basal cell carcinoma during a follow-up from 2000 to 2010. Researchers observed that participants who took Sildenafil (Viagra) were at almost twice the risk for developing the dangerous skin cancer melanoma. Researchers noted that they supported a need for continual investigation into the association of Viagra with melonoma skin cancer, but did not observe an increase in risks associated with Viagra and other sildenafil drug use and the different types of skin cancers. [archinte.jamanetwork.com/article.aspx?articleid=1857095, June 2014]

In a commentary that accompanied the article, Dr. June K. Robinson, of the Department of Dermatology at Northwestern University Feinberg School of Medicine in Chicago, and editor of JAMA Dermatology, wrote that a prospective study with clearly defined criteria and known doses of sildenafil taken is needed before recommending changes in how men use sildenafil. According to Dr. Robinson, about 76,100 new melanomas will be diagnosed in 2014, and an estimated 9,710 men and women will die as a result of the diagnosis. However, patients in the very early stage of the disease have a 5-year survival rate of 99 percent when the cancer is treated with excision, according to Dr. Robinson. Those who are in Stage IIB, when the tumor has spread further into the lower part of the skin, have a 5-year survival rate of 57 percent. Dr. Robinson wrote that early detection of melanoma is needed and surgical excision of the cancer is critical. [archinte.jamanetwork.com/article.aspx?articleid=1857089, June 2014]

Viagra was approved in 1998 by the U.S. Food & Drug Administration as a prescription medication to treat erectile dysfunction in men. The drug became known as the “blue pill” because of its distinct blue color. Pfizer Inc., the maker of Viagra, and other manufacturers of drugs that treat erectile dysfunctio such as Cialis and Levitra, were told by the FDA in July 2005 to update there labels to include sudden vision loss as a side-effect of taking the drug. Two years later, the FDA required the drug manufacturers to display more prominently the potential risk for sudden hearing loss and what consumers should do if they experience hearing problems. Since hearing loss is associated with the aging process, the FDA suggested that some men who use Viagra may not think to talk to their doctor about it. Currently, the Viagra labeling includes other risks of side-effects, such as headache, upset stomach, back pain, muscle pain, nausea and dizziness. Priapism, an erection that will not go away, has also been reported by men who have taken the drug. It is recommended that men seek medical attention immediately if they experience this serious side-effect.
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108458.htm, July 8, 2005]
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109012.htm, October 18, 2007]

If You Believe You Have Developed Melanoma or Skin Cancer Due To Use of Viagra or other Sildenafil Medications Contact The Oliver Group P.C. To Learn More About Your Legal Options

The Oliver Law Group P.C. is a different kind of national law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.

The experience of a large firm. The 1-on-1 dedication of a small firm. A reputation built on trust.
Experience. Dedication. Trust. Oliver Law Group P.C.

If you have developed melanoma skin cancer as a result of taking Sildenafil citrate, also known as Viagra, Revatio and under various other trade names,, turn to the law firm with the Experience, Dedication, and Trust you deserve. Contact the Oliver Law Group P.C. for your free Sildenafil melanoma skin cancer lawsuit case review by calling 1-800-939-7878 today or visit http://www.legalactionnow.com.

Alyson Oliver, The Oliver Law Group, http://www.legalactionnow.com, +1 800-939-7878, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.